Skip to main content
. 2021 Aug 20;3(3):429–441. doi: 10.3390/clockssleep3030030

Figure 1.

Figure 1

The locomotor activity profiles measured for CS males treated with lifespan modifying doses of KL001 и KS15 until the age of 5–12 days: (a,d)—activity per day in LD and DD; (b,e)—activity distributions in LD and DD; (c,f)—mean activities in LD and DD; (g)—profile of locomotor activity in LD, measured as an average per minute; (h)—actograms, presenting and comparing all the profile during six days of test, first to lines are LD, last four—DD in all three blocks; *—p < 0.0001 significant results, according to ANOVA with Tukey/Kramer procedure, p < 0.01 with Scheffe’s procedure for KS15 (c,f); *—p < 0.05, Mann-Whitney test for control vs. KL001 comparison. The effect on locomotor activity was observed both in LD and DD for KL001 cohort and for KS15 in DD, the daily activity profile in LD was elevated by KL001 5 µM solution in young age.